Welcome to the 21st WCP Virtual Congress Program Scheduling

The congress will officially run on Colombian Standard Time (UTC-5)

To convert the congress times to your local time Click Here         

        

Filter - Live Sessions: Plenary / Presidential Session   |   Courses   |  Special Sessions  |  Presidential Forum  |  Spanish Language Sessions |  State of the Art Sessions  |  Interorganizational Symposia  |  Original Sessions | Panel Discussions | Thematic Sessions

Filter - Recorded Sessions:  Accepted SymposiaFree Communications | WPA Distinguished Lectures

Displaying One Session

Accepted Symposia

Session Type
Symposium
Date
10/16/2021
Session Time
08:00 AM - 09:00 AM
Room
Accepted Symposia
Chair(s)
  • Jose Rubio (United States of America)
Session Description
Psychotic disorders are often characterized by recurrent relapses over the course of illness. Relapse impacts occupational and social functioning, undoes the progress made towards recovery and may endanger the patient and others. This symposium will address the major challenges, recent advances, and future directions in relapse-prevention in psychotic disorders. One of the major challenges is non-adherence with maintenance treatment. Dr Heidi Taipale (Finland) will present data on treatment continuity with antipsychotic drugs over the long-term in schizophrenia, as well as intervention targets to reduce treatment interruptions, including long-acting injectable antipsychotics. Despite the consistent literature supporting their efficacy, these formulations are largely underutilized. Some of the reasons are related to the challenges to present this treatment option effectively to patients. Dr John Kane (United States), will discuss how to make an effective presentation of a trial with a long-acting injectable antipsychotic. Another strategy to reduce treatment interruptions is to provide financial incentives to continue on treatment. Dr Daniel Guinart (Spain) will present data on the use of behavioral economics approaches to increase treatment adherence in psychotic disorders. Finally, although continuity with antipsychotic maintenance treatment has the best level of evidence for relapse-prevention, important challenges remain. About 20% of individuals with psychotic disorders do not relapse without maintenance treatment with antipsychotics. Alternatively, for 20-30% of individuals with psychotic disorders antipsychotics may not prevent subsequent relapses. Dr Jose Rubio (United States) will discuss future directions in stratifying maintenance treatment for individuals with psychotic disorders, to maximize the risk/benefit ratio of long-term antipsychotic treatment.

LONG-TERM TREATMENT CONTINUITY WITH ANTIPSYCHOTIC DRUGS IN SCHIZOPHRENIA

Presenter
  • Heidi Taipale (Finland)
Lecture Time
08:00 AM - 08:20 AM

COMPUTERIZED ADAPTIVE TESTING IN PSYCHOSIS: OPPORTUNITIES FOR RELAPSE PREVENTION

Presenter
  • Daniel Guinart (Spain)
Lecture Time
08:20 AM - 08:40 AM

HOW TO MAKE AN EFFECTIVE PRESENTATION OF A TRIAL WITH A LONG ACTING INJECTABLE ANTIPSYCHOTIC

Presenter
  • John Kane (United States of America)
Lecture Time
08:40 AM - 09:00 AM